Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||GSK3145095 + Pembrolizumab|
GSK3145095, a small molecule RIPK-1 inhibitor with potential antineoplastic and immunomodulatory activities that may reduce CXCL1-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells, and allows Natural Killer and Cytotoxic T Lymphocytes to eliminate cancer cells. (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|GSK3145095||GSK 3145095|GSK-3145095||GSK3145095 is a small molecule that inhibits RIPK1, resulting in decreased downstream signaling, and potentially leading to reduced recruitment of immunosuppressive cells in the tumor microenvironment and increased tumor cell death (NCI Drug Dictionary).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, and with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03681951||Phase Ib/II||GSK3145095 GSK3145095 + Pembrolizumab||First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors||Terminated|